Introduction
============

In China, sodium intake is high (mean 4.1 g/day, more than double the limit recommended by the World Health Organization),[@ref1] and nearly half (45%) of the Chinese population aged 35-75 have hypertension.[@ref2] In 2015, the annual number of deaths related to elevated systolic blood pressure was estimated at 2.3 million in China, an increase of 89% from 1990.[@ref3] High intake of sodium (\>2 g/day) is believed to cause more than one in seven of deaths from cardiovascular disease in China, and almost 30% of fatal strokes in those younger than 70 years are attributable to high consumption of sodium.[@ref4]

The largest contributor to dietary sodium in Chinese homes is discretionary salt (that is, salt used at table or during cooking), contributing to about 70% of sodium intake in the 2015 China Health and Nutrition Survey.[@ref1] Hence a promising strategy to reduce dietary consumption of sodium is to replace dietary salt (sodium chloride) with lower sodium salt substitutes, where sodium chloride is partially replaced with non-sodium alternatives. These salt substitutes typically use potassium chloride as the main replacement, with smaller amounts of taste enhancers. Salt substitutes are available for standard table salt and other key sources of sodium, such as soy sauce. In meta-analyses of randomised controlled trials, potassium enriched salt substitutes (25-67% potassium chloride), compared with standard salt (100% sodium chloride), reduced average systolic blood pressure by 5 mm Hg and diastolic blood pressure by 2 mm Hg.[@ref5] [@ref6] Potassium enriched salt substitutes were associated with a lower risk of death from cardiovascular disease in a cluster randomised trial in older Taiwanese adults.[@ref7] These findings have generated interest in the use of potassium enriched salt substitutes as a public health intervention to reduce diseases related to high blood pressure. The overall potential effect of potassium enriched salt substitutes to replace discretionary dietary salt in China, however, has not been quantified.

Concerns have been raised that potassium enriched salt substitutes might increase the risk of clinically important hyperkalaemia in individuals with advanced chronic kidney disease, increasing the risk of sudden cardiac death.[@ref8] Individuals with chronic kidney disease are advised to limit dietary potassium and avoid potassium enriched salt substitutes.[@ref9] In China, where most people with advanced chronic kidney disease are unaware of their condition,[@ref10] the risk of hyperkalaemia from a population based salt substitution is particularly relevant.

We modelled the effects of a national intervention to replace discretionary dietary salt with potassium enriched salt substitutes on morbidity and death from cardiovascular disease in China. The evaluation was designed to account for the benefits of lowering systolic blood pressure (and downstream diseases) and the potential consequences of hyperkalaemia.

Methods
=======

Study design
------------

We used comparative risk assessment models to estimate the overall effect of a nationwide intervention of potassium enriched salt substitution on the cardiovascular disease burden in China ([fig 1](#f1){ref-type="fig"}). The model for estimating the benefits of this intervention was based on the blood pressure lowering effect of potassium enriched salt substitutes compared with standard salt, with results stratified by age and sex (referred to here as the blood pressure model). A separate model for estimating harms related to salt substitute use was based on the anticipated change in serum concentrations of potassium in individuals with chronic kidney disease (defined as an estimated glomerular filtration rate \<60 mL/min/1.73 m^2^, relating to chronic kidney disease stages ≥G3a), stratified by chronic kidney disease stage (referred to here as the potassium model). The net effect of the intervention, including benefits and harms, was estimated in the total population and specifically in those with chronic kidney disease.

![Conceptual models used to estimate benefits, harms, and net effects of replacing dietary salt (sodium chloride) with potassium enriched salt substitutes. Distribution of potassium enriched salt substitutes to replace dietary salt was expected to reduce blood pressure in the adult population, with greater effects at older ages. In 24 age-sex groups, blood pressure distribution before the intervention and the lower blood pressure distribution after the intervention (that is, after replacement) were used to calculate a potential impact fraction (PIF), with risk estimates for blood pressure on outcomes of cardiovascular disease, for each of 11 subtypes of cardiovascular disease. The age, sex, and subtype specific PIF was multiplied by the pre-intervention estimates of the same groups for deaths from cardiovascular disease, non-fatal events, or disability adjusted life years to estimate the number of averted deaths, non-fatal events, or disability adjusted life years. In each age-sex group, the total number of averted deaths from cardiovascular disease, prevalence of chronic kidney disease, and the death risk from cardiovascular disease in patients with chronic kidney disease (compared with others) were used to estimate the number of averted deaths from cardiovascular disease attributed to individuals with chronic kidney disease. For each chronic kidney disease stage (G3a, G3b, G4, and G5), estimates of the expected increase in potassium intake from replacement of dietary salt with potassium enriched salt substitutes, the dose-response relation of dietary and serum potassium, and pre-intervention serum potassium distribution were used to estimate the post-intervention serum potassium distribution. The serum potassium distributions (before and after the intervention) and known risk estimates of serum potassium with deaths from cardiovascular disease were used to calculate a PIF for each chronic kidney disease stage. The PIF and stage specific estimate of pre-intervention deaths from cardiovascular disease were used to calculate the additional deaths from cardiovascular disease. The additional deaths were subtracted from averted deaths to estimate net benefits (averted deaths) in individuals with chronic kidney disease exclusively and in the total adult population, including those with chronic kidney disease. [Table 1](#tbl1){ref-type="table"} presents the model inputs and the appendix provides detailed information and rationales on model calculations and assumptions](marm052964.f1){#f1}

Intervention
------------

The modelled policy was a nationwide salt substitution intervention based on the Salt Substitute and Stroke Study, a large scale, cluster randomised controlled trial currently being conducted in 600 villages across five provinces in rural areas of northern China (clinicalTrials.gov NCT02092090) to estimate the effect of salt substitutes on risk of stroke.[@ref11] [@ref12] The salt substitute used in the Salt Substitute and Stroke Study, manufactured according to national manufacturing standards (which requires 70±10% sodium chloride and 30±10% potassium chloride), was purchased from a local provider in each county. Sufficient amounts of potassium enriched salt substitutes (average 25% potassium chloride) were distributed quarterly, free of charge, to cover household cooking and food preservation (average 20 g/day for each person). Monitoring was done at the time of distribution to confirm that the quantity of salt substitute provided was adequate to replace typical salt use by the household. Participants were given oral, written, and other reminders (eg, on cooking aprons) to reinforce use of the salt substitute.[@ref12] Participants were also advised to use the salt substitute more sparingly, and not more often, than previous use of dietary salt. This pragmatic trial provides a real world approximation of the overall intensity, coverage, compliance, and effects on systolic blood pressure of a potassium enriched salt substitute intervention in China.

Data sources
------------

### Blood pressure model (potential benefits)

[Table 1](#tbl1){ref-type="table"} and eTables 1-5 present model inputs and assumptions. We used the 2015 age and sex specific estimates of mean systolic blood pressure (eTable 1) and outcomes for cardiovascular disease and chronic kidney disease for China from the Global Burden of Disease Study.[@ref3] [@ref13] [@ref14] [@ref15] Cardiovascular disease outcomes included death, non-fatal cardiovascular events, and disability adjusted life years (defined as the sum of years lost as a result of premature death and years lived with disability) related to cardiovascular disease, overall and for each cardiovascular disease subtype, including ischaemic heart disease, stroke (ischaemic and haemorrhagic), and other cardiovascular diseases. Based on age and sex specific systolic blood pressure distributions estimated in more than 500 000 Chinese adults,[@ref16] we assumed that the standard deviation of systolic blood pressure in each age-sex group was equal to 15% of the mean for that specific group. In our primary model, we used the effect of a salt substitute on systolic blood pressure based on an evaluation of interim measurements (1-3 years after baseline) of 4705 participants in the ongoing Salt Substitute and Stroke Study (appendix 1). The use of salt substitutes was associated with lowered systolic blood pressure and the effects increased with age ([table 1](#tbl1){ref-type="table"}, eTables 2 and 3, and appendix 1). At a baseline age of 65, systolic blood pressure was reduced by 2.82 mm Hg (95% confidence interval 0.89 to 4.75, P=0.004), and for each additional year of age, the effect was 0.13 mm Hg (−0.02 to 0.27, P=0.09) larger for older ages or smaller for younger ages. The effects of changes in systolic blood pressure on cardiovascular disease outcomes, and the risk of chronic kidney disease, were based on the Global Burden of Disease Study and our previous meta-analysis (eTable 4). The prevalence of chronic kidney disease in each age and sex group was estimated by interpolation and extrapolation based on piecewise linear regression of the sex specific prevalence of chronic kidney disease in four age groups from the China National Survey of Chronic Kidney Disease,[@ref17] plotted against the midpoint age of each age group (appendix 2). Age specific hazard ratios for death from cardiovascular disease in individuals with chronic kidney disease (compared with others in the same age group) were estimated by interpolation and extrapolation of the log hazard ratio in four age groups,[@ref18] plotted against the midpoint age of each age group (appendix 2).

###### 

Input data for comparative risk assessment on effect of nationwide salt substitute intervention in the adult Chinese population on cardiovascular disease burden

  Model and data                                                         Group              Year      Value                                                                                                                                                                   Distribution   Note                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Source
  ---------------------------------------------------------------------- ------------------ --------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------
  **Blood pressure**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  Pre-intervention SBP                                                   Sex, age           2015      Age and sex specific estimates (eTable 1)                                                                                                                               γ              Standard deviation of SBP in each group (Chinese adults aged ≥25) was assumed equal to 15% of the mean for that specific group, based on age and sex specific SBP distributions estimated in \>500 000 Chinese adults.[@ref16] For each iteration (n=1000), random draws from normal distributions of age-sex specific means from GBD were used to calculate assumed standard deviation and γparameters                                                                                                                                                                                             GBD, 2017\*
  Intervention effect on SBP                                             Age                N/A       −2.82 (−4.75 to −0.89) mm Hg at age 65 years, with 0.13 (−0.02 to 0.27) mm Hg lesser or greater reduction for each year of age younger or older than 65, respectively   Normal         Estimates and their uncertainties of treatment effect and age-treatment interaction were estimated using interim measurements (1-3 years after baseline) in \>4500 participants of the SSaSS. For each iteration (n=1000), random draws from normal distributions of main and interaction effects were used to calculate age specific effects on SBP                                                                                                                                                                                                                                                SSaSS (unpublished)†
  SBP effect on CVD risk                                                 Age                N/A       Disease and age specific estimates (eTable 4)                                                                                                                           Log normal     For each iteration (n=1000), random draws of age specific log relative risks of CVD subtypes (n=8) were made                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        GBD, 2017\* Singh[@ref23]
  SBP effect on CKD risk                                                 N/A                N/A       RR 1.28 (95% CI 1.18 to 1.39) per 10 mm Hg                                                                                                                              Log normal     For each iteration (n=1000), random draws of log RR were made                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       GBD, 2014‡
  Current CVD and CKD burden                                             Sex, age           2015      Disease, sex, and age specific estimates                                                                                                                                Normal         Estimates and corresponding 95% uncertainty intervals for CVD subtypes (n=11) and CKD were retrieved from the GBD Results Tool                                                                                                                                                                                                                                                                                                                                                                                                                                                                      GBD Results Tool§
  Prevalence of CKD (%)                                                  Sex, age           2007-10   Age and sex specific estimates (eTable 1)                                                                                                                               Normal         Age and sex specific prevalence of CKD (eGFR \<60 mL/min/1.73m^2^) was estimated by interpolation and extrapolation based on piecewise linear regression of age specific CKD prevalence in four age groups (18-39, 40-59, 60-69, ≥70[@ref17]) plotted against the midpoint age of each age group. Similarly, 95% CIs for prevalence of CKD were estimated by interpolation and extrapolation based on piecewise linear regression of upper and lower 95% CI boundaries. For each iteration (n=1000), random draws of age and sex specific CKD prevalence (assuming normal distribution) were made   Zhang[@ref17]
  Age specific HR of CVD mortality in CKD compared with non-CKD          Age                N/A       Age specific HR estimates (eTable 1)                                                                                                                                    Log normal     Age specific (18-54, 55-64, 65-74, ≥75) HRs comparing eGFR 50 *v* 80 mL/min/1.73m^2^ were assessed by Hallan[@ref18] in individual level meta-analysis of \>2 million participants. We conducted linear extrapolation and interpolation of natural logarithms of the multivariable adjusted HRs plotted against the midpoint ages of the age groups evaluated by Hallan,[@ref18] to estimate HRs in 5 year age intervals                                                                                                                                                                            Hallan[@ref18]
  **Potassium**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Prevalence of CKD by stage (%)                                         CKD stage¶         2007-10   Stage G3a: 1.40 (95% CI 1.20 to 1.50); stage G3b: 0.20 (0.10 to 0.30); stage G4: 0.10 (0.06 to 0.20); stage G5: 0.03 (0.01 to 0.05)                                     Normal         Prevalence of CKD per eGFR level in the adult Chinese population. Random draws were made for each iteration (n=1000)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Zhang[@ref17]
  Crude HR of CVD mortality compared with non-CKD                        CKD stage¶         N/A       Stage G3a: 4.03 (95% CI 2.76 to 5.88); stage G3b: 6.95 (4.35 to 11.10); stage G4: 9.93 (6.09 to 16.17); stage G5: 17.51 (9.72 to 31.55)                                 Log normal     Unadjusted HRs for each CKD stage using midpoint eGFR (ie, stage G3a 52.5, stage G3b 37.5, stage G4 22.5, stage G5 7.5 mL/min/1.73m^2^) *v* reference point (eGFR 95 mL/min/1.73m^2^) were extracted from eFig 7b in Matsushita.[@ref19] For each iteration (n=1000), random draws of stage specific HR (assuming log normal distribution) were made and used to calculate pre-intervention CVD deaths per CKD stage                                                                                                                                                                                Matsushita[@ref19]
  Mean (SD) current serum potassium distribution (mmol/L)                CKD stage[@ref4]   N/A       Stage G3a: 4.34 (0.45); stage G3b: 4.42 (0.51); stage G4: 4.52 (0.59); stage G5: 4.63 (0.67)                                                                            Normal         Extrapolated and interpolated from linear regressions of means and standard deviations of stage G3 and ≥G4 reported by the CKD-PC. For each iteration (n=1000), random draws of stage specific serum potassium levels (assuming normal distribution) were made                                                                                                                                                                                                                                                                                                                                      Kovesdy[@ref8]
  Increase in potassium intake by salt substitute intervention (g/day)   N/A                N/A       0.86 (95% CI 1.14 to 0.68)                                                                                                                                              Normal         Calculated by multiplying urinary excretion in SSaSS (0.66 g/24 hours; 95% CI 0.52 to 0.80) by a factor of 1.3 based on mean differences between intake and excretion[@ref20]                                                                                                                                                                                                                                                                                                                                                                                                                       Huang 2018\*\*
  Dietary potassium effect on serum potassium level (mmol/L per g/day)   CKD stage[@ref4]   N/A       Stage G3a: 0.23 (95% CI 0.08 to 0.38); stage G3b: 0.47 (0.33 to 0.61); stage G4: 0.93 (0.66 to 1.21); stage G5: 1.87 (1.33 to 2.41)                                     Normal         Estimated in clinical trial; β and SE assumed to be 2× effect estimated in stage G3a; β and SE assumed to be 4× effect estimated in stage G3a; β and SE assumed to 8× effect estimated in stage G3a                                                                                                                                                                                                                                                                                                                                                                                                 Turban (unpublished)††
  Serum potassium effect on CVD mortality                                N/A                N/A       HR (95% CI) compared with serum potassium 4.2 mmol/L available for each 0.05 increment of serum potassium in the interval 4.2 to 6.5 mmol/L                             Log normal     CKD-PC data suggest no evidence of different HR per eGFR level                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Kovesdy[@ref8]

β=regression coefficient of serum to dietary potassium; CKD=chronic kidney disease; CKD-PC=Chronic Kidney Disease Prognosis Consortium; CVD=cardiovascular disease; eGFR=estimated glomerular filtration rate; GBD=Global Burden of Disease Study; HR=hazard ratio; N/A=not applicable; SBP=systolic blood pressure; SD=standard deviation; SE=standard error; SSaSS=Salt Substitute and Stroke Study; RR=relative risk.

2015 blood pressure levels by age and sex were extracted from the Global Burden of Disease Study 2015. Hypertension and systolic blood pressure of at least 110 to 115 mm Hg 1990-2015. Seattle: Institute for Health Metrics and Evaluation (IHME), 2017.[@ref3]

Effects on systolic blood pressure and potassium intake were assessed in the ongoing Salt Substitute and Stroke Study, a cluster randomised trial conducted in 600 villages across five Chinese provinces.

Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration. Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: a comparative risk assessment. *Lancet Diabetes Endocrinol* 2014;2:634-47 (reference 10 from web appendix).

Data (estimates and uncertainties) on deaths from cardiovascular disease by age and sex were retrieved from the Institute for the GBD Results Tool (Health Metrics and Evaluation (IHME) GBD Results Tool). Seattle, WA: IHME, University of Washington, 2019. <http://ghdx.healthdata.org/gbd-results-tool>.

Chronic kidney disease stages: G3a (estimated glomerular filtration rate 45-59 mL/min/1.73 m^2^); G3b (30-44); G4 (15-29); and G5 (\<15-29).

Increase in intake of potassium was assessed using 24 hour urinary excretion of potassium from the ongoing Salt Substitute and Stroke Study, a cluster randomised trial conducted in 600 villages across China.

The effects of dietary potassium on blood pressure in adults with stage 3 chronic kidney disease: Results from the CKD-K trial (unpublished data).

### Potassium model (potential harms)

To estimate death rates from cardiovascular disease by stage of chronic kidney disease, before the intervention, we used: the 2015 estimates of deaths from cardiovascular disease from the Global Burden of Disease Study; the prevalence of each stage of chronic kidney disease from the China National Survey of Chronic Kidney Disease[@ref17]; and hazard ratios for death from cardiovascular disease by stage of chronic kidney disease from the Chronic Kidney Disease Prognosis Consortium.[@ref19] The estimated increase in potassium intake from salt substitution (30±10% potassium chloride) was based on the increase in urinary excretion of potassium in 24 hours in the Salt Substitute and Stroke Study, multiplied by a factor of 1.3, based on the mean differences between intake and excretion (appendix 3).[@ref20]

We used data from an unpublished randomised controlled trial (clinicalTrials.gov NCT00949585) investigating potassium supplementation in patients with moderate chronic kidney disease to estimate the dose-response relation between dietary and serum potassium in patients with chronic kidney disease stage G3a (appendix 4). The two period crossover trial included 29 patients with chronic kidney disease stage G3a (mean estimated glomerular filtration rate 54.5 mL/min/1.73 m^2^; mean age 67; 59% women; 24% with diabetes; 93% with hypertension; and 59% receiving angiotensin converting enzyme inhibitors or angiotensin II receptor blockers) who were assigned to diets providing 100 and 40 mmol/day of potassium in two four week periods. We used serum measurements of potassium obtained one week after the start of each feeding period. Mean serum concentration of potassium was 0.55 (95% confidence interval 0.38 to 0.72) mmol/L greater at the higher dose compared with the lower dose, which is equivalent to 0.23 (0.08 to 0.38) mmol/L greater serum concentration of potassium for each additional gram of dietary potassium daily.

Based on a recent expert consensus statement, we assumed that measurable changes in serum concentrations of potassium from a potassium enriched salt substitute could occur in chronic kidney disease stages G3a and higher.[@ref21] [@ref22] In the primary model, we assumed that the dose-response relation in chronic kidney disease stage G3a would double with each increasing stage of chronic kidney disease (appendix 4). We derived means and standard deviations of serum concentrations of potassium for each of four chronic kidney disease stages (G3a, G3b, G4, and G5) by extrapolation of data reported for stages G3a-G3b and G4-G5 in a pooled analysis of 25 international cohorts (appendix 4).[@ref8] We used relative risks of serum potassium with deaths from cardiovascular disease from the same pooled analysis.[@ref8]

Statistical analysis
--------------------

### Blood pressure model

Incorporating estimates and uncertainty for systolic blood pressure measurements and outcomes in the 2015 population, the intervention effects on systolic blood pressure, and the associations of systolic blood pressure with risk of cardiovascular disease and chronic kidney disease, we calculated the potential impact fraction of the intervention for each outcome, separately in 24 age and sex groups, overall and in the subset of the population with chronic kidney disease (appendix 2). The potential impact fraction (PIF) for each outcome (o) was defined as: PIF~oas~=(∫^m^ ~x=0~RR~oa~(x)P~as~(x)dx−∫^m^ ~x=0~RR~oa~(x)P'~as~(x)dx)÷(∫^m^ ~x=0~RR~oa~(x)P~as~(x)dx), where P~as~(x) and P'~as~(x) are the pre-intervention and post-intervention systolic blood pressure distributions in age group (a) and sex (s). RR~oa~(x) is the relative risk as a function of systolic blood pressure (x), outcome (o), and age (a): RR~oa~(x)=e^(lnRRoa(x−TMREL)÷10)^, where lnRR~oa~ is the increase in the natural logarithm of the relative risk of outcome (o) in age (a) for each 10 mm Hg increase in systolic blood pressure, derived from previous meta-analyses,[@ref3] [@ref23] and TMREL is the theoretical minimum risk exposure level (that is, 110-115 mm Hg).[@ref3]

The number of cardiovascular events prevented were computed by multiplying an age, sex, and cause specific potential impact fraction by the estimated current number of cardiovascular events for the same group. The total numbers of averted events were calculated as the sum of estimates over all groups and we summed subtype specific estimates to generate estimates for total cardiovascular disease. We excluded inflammatory heart diseases from the estimations of non-fatal events and disability adjusted life years because these diseases develop independently of increases in blood pressure. These conditions were included in the estimation of death rates, however, because a lower blood pressure will benefit and reduce deaths from heart failure similarly in those individuals.[@ref23] In each group, we also computed prevented deaths from cardiovascular disease in individuals with chronic kidney disease (appendix 2).

### Potassium model

To estimate the additional deaths from cardiovascular disease from increased intake of potassium in individuals with chronic kidney disease, we computed the potential impact fraction (PIF) for deaths from cardiovascular disease for each stage of chronic kidney disease (e) as: PIF~e~=(∑^m^ ~x=0~ RR(x)P~e~(x)−∑^m^ ~x=0~ RR(x)P'~e~(x))÷(∑^m^ ~x=0~ RR(x)P~e~(x)), where P~e~(x) and P'~e~(x) are the pre-intervention and post-intervention distributions of serum potassium in chronic kidney disease stage e. RR(x) is the relative risk of death from cardiovascular disease at serum potassium concentration x, and was reported for each 0.05 mmol/L increase in serum potassium in a pooled analysis of 25 cohort studies.[@ref8] The additional deaths from cardiovascular disease (that is, negative of averted deaths from cardiovascular disease) from the intervention were computed by multiplying the negative of the potential impact fraction in each group by the number of deaths from cardiovascular disease in the same group before the intervention. We summed group specific effects to derive total additional deaths for all individuals with chronic kidney disease.

### Estimating intervention net effects on deaths from cardiovascular disease

The net averted deaths from cardiovascular disease were calculated as the difference between averted deaths caused by a reduction in systolic blood pressure and additional deaths caused by an increase in serum concentrations of potassium (appendix 5). We also calculated the benefit-to-risk ratio by dividing the averted deaths from a reduction in systolic blood pressure by the additional deaths related to hyperkalaemia. The net effects, expressed as absolute number, percentage of current number of deaths from cardiovascular disease, and the benefit-to-risk ratio, were calculated for the whole population and for those with chronic kidney disease.

### Uncertainty analysis

We quantified uncertainty in all analyses with probabilistic sensitivity analyses in Monte Carlo simulations, jointly incorporating group specific uncertainties in input parameters. For each simulation, a draw was made from the distributions of: current mean systolic blood pressure for the specific age-sex group; the theoretical minimum risk exposure level; the effect of salt substitutes on systolic blood pressure; the age-salt substitute interaction effect on systolic blood pressure; the effects of systolic blood pressure on each cardiovascular disease outcome; the current number of events (eg, deaths) for each cardiovascular disease outcome; the prevalence of chronic kidney disease in each group; and the hazard ratio for deaths from cardiovascular disease in patients with chronic kidney disease compared with others in the same age group. Uncertainty in the theoretical minimum risk exposure level was propagated by sampling between the 110-115 mm Hg interval each time the potential impact fraction was calculated.[@ref3] For each simulation of the potassium model, a draw was made from the distributions of: increased potassium intake; total deaths from cardiovascular disease; stage specific prevalence of chronic kidney disease; and relative risk of serum potassium with deaths from cardiovascular disease. Similarly, draws were made for the group specific distributions of: risk of deaths from cardiovascular disease; relation between diet and serum potassium; and serum concentrations of potassium. For each simulation of the blood pressure and potassium models, the net averted deaths were calculated as the difference between averted and additional deaths. We derived the corresponding central estimate for each endpoint (including benefits, harms, and net effects) from the 50th centile, and the 95% uncertainty interval from the 2.5th and 97.5th centiles of 1000 modelling runs.

### Sensitivity analyses

In our primary model, we used a conservative approach in selecting input data to avoid overestimation of benefits and underestimation of harms. A strength of modelling approaches is the ability to assess how findings can vary in response to a range of reasonable assumptions. To evaluate the robustness of the primary model, we conducted several sensitivity analyses by changing key model assumptions and inputs (appendix 6 and eTable 6). We evaluated the impact of varying intervention coverage by assuming 50% higher or 50% lower reductions in systolic blood pressure and increases in potassium intake compared with that observed in the Salt Substitute and Stroke Study. We estimated the net effect on deaths from cardiovascular disease assuming that all individuals with chronic kidney disease, aware of their diagnosis (about 14% of individuals with chronic kidney disease stages ≥G3a),[@ref10] [@ref17] would avoid salt substitutes; for this sensitivity analysis, we used published data on prevalence[@ref17] and awareness[@ref10] of chronic kidney disease in China, and assumed neither benefits nor risks of the intervention in the proportion of individuals with chronic kidney disease who were aware of their diagnosis.

Using alternative effects from three meta-analyses of studies of salt substitutes, we varied the impact of potassium enriched salt substitutes on systolic blood pressure.[@ref5] [@ref6] [@ref24] Hernandez et al evaluated the effects on systolic blood pressure and urinary excretion of potassium in salt substitute trials.[@ref24] Thus we used estimates for reduction in systolic blood pressure and potassium excretion to simultaneously change our assumptions on potassium intake and effects on systolic blood pressure (eTable 6). Whereas a reduction in sodium is associated with lower systolic blood pressure in people with normal and high blood pressure,[@ref4] and meta-analyses of salt substitute trials have consistently reported reductions in blood pressure in individuals with hypertension,[@ref5] [@ref6] [@ref24] limited evidence exists for the effects of salt substitutes on systolic blood pressure in people with normal blood pressure.[@ref5] [@ref6] [@ref24] Thus we conducted a sensitivity analysis assuming no effect of salt substitution on systolic blood pressure in people with normal blood pressure based on the prevalence of hypertension by age and sex from a recent survey of 1.7 million Chinese people.[@ref2]

We evaluated the impact of a stronger or weaker dose-response relation between dietary and serum potassium by assuming that the serum response increases either exponentially or linearly, respectively, with decreasing estimated glomerular filtration rate, and investigated the impact of assuming the same serum response to potassium dose in chronic kidney disease stages G3b, G4, and G5 as estimated in stage G3a (eTable 6). We varied the standard deviation of systolic blood pressure in each age-sex group (10% and 20% of the mean). To evaluate how salt substitutes and potassium content influence the estimated additional deaths from cardiovascular disease in individuals with chronic kidney disease, we varied the proportion of discretionary salt replaced by salt substitutes (10-100%) and the content of potassium chloride in salt substitutes (10% or 25%).

Finally, we evaluated a hypothetical extreme scenario with a combination of assumptions to maximise the number of estimated additional deaths due to hyperkalaemia but limiting the number of estimated averted deaths from a reduction in blood pressure, including assuming: 50% greater use of salt substitutes; the benefits on blood pressure occurring exclusively in individuals with hypertension; and an exponential increase in the relation between diet and serum potassium by declining kidney function. All analyses were performed with RStudio, version 1.1.423.

Patient and public involvement
------------------------------

No patients were involved in setting the research question or the outcome measures, nor were they involved in developing plans for design or implementation of the study. No patients were asked to advise on interpretation or writing up of results.

Results
=======

The overall effects of salt substitution on systolic blood pressure were estimated to prevent about 461 000 deaths (95% uncertainty interval 196 339 to 704 438) from cardiovascular disease annually, including 208 000 (89 366 to 328 249) due to stroke and 175 000 (71 016 to 271 720) due to ischaemic heart disease ([table 2](#tbl2){ref-type="table"}). These averted deaths corresponded to 10.9% (4.7% to 16.8%) of baseline deaths from cardiovascular disease. The effects of the intervention on systolic blood pressure could also avert an estimated 743 000 (305 803 to 1 273 098) non-fatal cardiovascular events annually, including about 365 000 (150 524 to 623 309) strokes, 147 000 (62 335 to 241 590) ischaemic heart disease events, and 7.9 million (3.3 to 12.9) disability adjusted life years related to cardiovascular disease annually. The effects on systolic blood pressure were also estimated to decrease the incidence of chronic kidney disease by about 120 000 (47 889 to 199 075) annually, corresponding to 6.9%(2.8% to 11.4%) of the total number of cases of incident chronic kidney disease.

###### 

Estimated intervention effects on cardiovascular disease and chronic kidney disease in total adult population in China by nationwide intervention replacing discretionary salts (salt used at table and in cooking) with potassium enriched salt substitutes

  Metric and disease                        Current No (000s) of events (95% UI)   Averted No of events (95% UI)   
  ----------------------------------------- -------------------------------------- ------------------------------- --------------------
  **Deaths/year**                                                                                                  
  Total cardiovascular disease\*            4201 (4157 to 4246)                    461 (196 to 704)                10.9 (4.7 to 16.8)
  Ischaemic heart disease                   1689 (1666 to 1715)                    175 (71 to 272)                 10.3 (4.2 to 16.2)
  Stroke:                                   2034 (2012 to 2056)                    208 (89 to 328)                 10.2 (4.4 to 16.1)
   Ischaemic                                815 (801 to 829)                       77 (32 to 123)                  9.4 (4.0 to 15.0)
   Haemorrhagic                             1219 (1201 to 1236)                    130 (56 to 209)                 10.7 (4.6 to 17.1)
  Other cardiovascular disease†             477 (448 to 506)                       75 (32 to 114)                  15.8 (6.9 to 23.6)
  Chronic kidney disease                    171 (167 to 176)                       15 (6 to 23)                    8.5 (3.6 to 13.3)
  **Non-fatal events/year**                                                                                        
  Total cardiovascular disease‡             9455 (9204 to 9727)                    743 (306 to 1273)               7.9 (3.2 to 13.4)
  Ischaemic heart disease                   1546 (1445 to 1657)                    147 (62 to 242)                 9.5 (4.0 to 15.5)
  Stroke¶:                                  4022 (3887 to 4161)                    365 (151 to 623)                9.1 (3.7 to 15.4)
   Ischaemic¶                               2636 (2503 to 2771)                    232 (96 to 385)                 8.8 (3.6 to 14.6)
   Haemorrhagic¶                            1386 (1340 to 1429)                    131 (52 to 239)                 9.5 (3.7 to 17.2)
  Other cardiovascular disease§             3891 (3697 to 4096)                    230 (82 to 418)                 5.9 (2.2 to 10.7)
  Chronic kidney disease                    1741 (1596 to 1885)                    120 (48 to 199)                 6.9 (2.8 to 11.4)
  **Disability adjusted life years/year**                                                                          
  Total cardiovascular disease\*\*          82 006 (81 292 to 82 722)              7947 (3310 to 12 891)           9.7 (4.0 to 15.7)
  Ischaemic heart disease                   29 804 (29 452 to 30 191)              2701 (1115 to 4390)             9.1 (3.7 to 14.7)
  Stroke:                                   42 554 (42 040 to 43 025)              4013 (1692 to 6620)             9.5 (4.0 to 15.5)
   Ischaemic                                17 401 (17 028 to 17 796)              1602 (678 to 2523)              9.2 (3.9 to 14.5)
   Haemorrhagic                             25 139 (24 806 to 25 468)              2397 (954 to 4183)              9.6 (3.8 to 16.6)
  Other cardiovascular disease††            9664 (9309 to 9987)                    1249 (563 to 1933)              12.9 (5.7 to 19.9)
  Chronic kidney disease                    4684 (4572 to 4793)                    303 (126 to 506)                6.5 (2.7 to 10.8)

UI=uncertainty interval.

Includes ischaemic heart disease, stroke (ischaemic and haemorrhagic), and other cardiovascular diseases (aortic aneurysm, hypertensive heart disease, rheumatic heart disease, endocarditis, atrial fibrillation, myocarditis, cardiomyopathy, peripheral artery disease, and other cardiovascular and circulatory diseases).

Includes aortic aneurysm, hypertensive heart disease, rheumatic heart disease, endocarditis, atrial fibrillation, myocarditis, cardiomyopathy, peripheral artery disease, and other cardiovascular and circulatory diseases.

Includes ischaemic heart disease, stroke (ischaemic and haemorrhagic), and other cardiovascular diseases (atrial fibrillation and peripheral artery disease).

Includes atrial fibrillation and peripheral artery disease.

Includes only first events.

Includes ischaemic heart disease, stroke (ischaemic and haemorrhagic), and other cardiovascular diseases (aortic aneurysm, hypertensive heart disease, atrial fibrillation, peripheral artery disease, and other cardiovascular and circulatory diseases), but not rheumatic heart disease, endocarditis, myocarditis, or cardiomyopathy.

Includes aortic aneurysm, hypertensive heart disease, atrial fibrillation, peripheral artery disease, and other cardiovascular and circulatory diseases, but not rheumatic heart disease, endocarditis, myocarditis, or cardiomyopathy.

Averted deaths from cardiovascular disease were mainly in older adults (≥70) because of the age related differences in the risk of death, but averted non-fatal cardiovascular events and disability adjusted life years were more evenly distributed across ages (eFigs 1-3). In about 17.2 million (95% uncertainty interval 14.6 to 19.7) individuals with chronic kidney disease (stages ≥G3a), the effects of the intervention on systolic blood pressure could prevent an estimated 32 000 deaths (12 261 to 54 453) from cardiovascular disease.

In individuals with chronic kidney disease (stages ≥G3a), increased intake of potassium and serum concentrations of potassium were estimated to potentially result in about 11 000 (95% uncertainty interval6422 to 16 562) additional deaths from cardiovascular disease ([table 3](#tbl3){ref-type="table"}). About half (42%) of the additional deaths related to hyperkalaemia were in individuals with advanced chronic kidney disease (stages G4-G5), who represent about 8% of all Chinese individuals with chronic kidney disease,[@ref17] and contribute to about 17% of current deaths from cardiovascular disease in individuals with chronic kidney disease (eTable 7).

###### 

Intervention effects on deaths from cardiovascular disease\* in patients with chronic kidney disease estimated by the primary model and one way deterministic sensitivity analyses

  Analyses                                                                 Averted deaths (000s) from reduction in SBP (95% UI)   Additional deaths (000s) from increased serum potassium (95% UI)   Net averted deaths from CVD (95% UI)   
  ------------------------------------------------------------------------ ------------------------------------------------------ ------------------------------------------------------------------ -------------------------------------- ---------------------
  **Primary model**                                                        32.2 (12.3 to 54.5)                                    10.6 (6.4 to 16.6)                                                 21.4 (1.9 to 42.9)                     7.5 (0.6 to 13.8)
  **Sensitivity analyses**                                                                                                                                                                                                                  
  Coverage:                                                                                                                                                                                                                                 
   Lesser (50% of primary model)                                           16.7 (6.2 to 28.6)                                     5.6 (3.3 to 8.7)                                                   11.1 (1.0 to 22.6)                     3.9 (0.3 to 7.4)
   Greater (150% of primary model)                                         46.6 (18.2 to 77.5)                                    14.9 (9.2 to 23.5)                                                 31.5 (3.2 to 61.0)                     11.1 (1.2 to 19.7)
  Patients aware of having chronic kidney disease avoid salt substitutes   31.9 (12.2 to 54.1)                                    8.5 (5.1 to 13.1)                                                  23.1 (3.9 to 44.6)                     8.2 (1.5 to 14.5)
  Alternative blood pressure effects of salt substitutes:                                                                                                                                                                                   
   About 75% greater[@ref5]                                                40.8 (22.2 to 66.9)                                    10.6 (6.4 to 16.6)                                                 30.3 (11.2 to 54.2)                    10.8 (3.8 to 17.6)
   About 100% greater[@ref6]                                               45.6 (29.3 to 68.2)                                    10.6 (6.4 to 16.6)                                                 35.0 (20.8 to 55.8)                    12.3 (8.3 to 16.8)
   About 180% greater[@ref24]†                                             61.8 (42.1 to 91.2)                                    10.6 (6.4 to 16.6)                                                 51.1 (34.9 to 76.3)                    17.8 (14.3 to 21.8)
   Effect only in people with hypertension                                 25.3 (10.7 to 44.4)                                    10.6 (6.4 to 16.6)                                                 14.7 (0.1 to 31.8)                     5.2 (0.0 to 10.5)
  Dose-response relation of serum to dietary potassium intake:                                                                                                                                                                              
   Stronger‡                                                               32.2 (12.3 to 54.5)                                    11.9 (6.9 to 19.1)                                                 20.1 (1.1 to 41.4)                     7.0 (0.4 to 13.6)
   Weaker§                                                                 32.2 (12.3 to 54.5)                                    7.5 (4.7 to 11.7)                                                  24.3 (5.2 to 45.9)                     8.6 (2.0 to 14.9)
   Equal over chronic kidney disease stages G3a-G5                         32.2 (12.3 to 54.5)                                    5.8 (3.6 to 9.0)                                                   26.1 (7.2 to 47.6)                     9.2 (2.7 to 15.4)

SBP=systolic blood pressure; UI=uncertainty interval; CVD=cardiovascular disease; CKD=chronic kidney disease.\*Include deaths from ischaemic heart disease, stroke (ischaemic and haemorrhagic), and other cardiovascular diseases (aortic aneurysm, hypertensive heart disease, atrial fibrillation, cardiomyopathy, peripheral artery disease, and other cardiovascular and circulatory diseases).

Hernandez et al conducted meta-analyses to evaluate the effect of salt substitutes on blood pressure and 24 hour excretion of potassium.[@ref24] Estimates for excretion of potassium in 24 hours (11.5 mmol/day, 95% confidence interval 8.4 to 14.6) were multiplied by a factor of 1.3 to estimate the corresponding increase in potassium intake and changed the assumptions of the effects of blood pressure and potassium intake in the sensitivity analysis.

Increasing exponentially with decreasing kidney function.

Increasing linearly with decreasing kidney function.

The estimated net effect of the modelled intervention was about 450 000 (95% uncertainty interval183 699 to 697 084) fewer deaths from cardiovascular disease annually in the overall population (about 11% of all deaths from cardiovascular disease) and around 21 000 (1928 to 42 926) fewer deaths from cardiovascular disease annually in individuals with chronic kidney disease (about 8% of all deaths from cardiovascular disease; [table 3](#tbl3){ref-type="table"} and [table 4](#tbl4){ref-type="table"}). The ratio of averted deaths caused by a reduction in systolic blood pressure compared with additional deaths due to hyperkalaemia was about 43:1 (95% uncertainty interval16:1 to 83:1) in the whole population and three to one (3.1:1, 1.2:1 to 5.4:1) in individuals with chronic kidney disease ([fig 2](#f2){ref-type="fig"}).

###### 

Intervention effects on deaths from cardiovascular disease\* in total adult population in China estimated by the primary model and one way deterministic sensitivity analyses\*

  Analyses                                                                 Averted deaths from SBP reduction in total population (95% UI)                          Additional deaths from increased serum potassium in patients with CKD (95% UI)                        Net averted deaths from CVD (95% UI)                                                        
  ------------------------------------------------------------------------ ---------------------------------------------------------------- ---------------------- -------------------------------------------------------------------------------- -------------------- -------------------------------------- -- -------------------------- ---------------------- ---------------------
  **Primary model**                                                        460.7 (196.3 to 704.4)                                           45.9 (19.8 to 71.9)                                                                                     10.6 (6.4 to 16.6)   1.1 (0.6 to 1.7)                          449.5 (183.7 to 697.1)     44.8 (18.8 to 70.8)    10.7 (4.4 to 16.5)
  **Sensitivity analyses**                                                                                                                                                                                                                                                                                                                                           
  Coverage:                                                                                                                                                                                                                                                                                                                                                          
   Lesser (50% of primary model)                                           239.1 (99.6 to 372.1)                                            23.8 (10.1 to 37.9)                                                                                     5.6 (3.3 to 8.7)     0.6 (0.3 to 0.9)                          233.3 (93.2 to 368.0)      23.2 (9.5 to 37.4)     5.5 (2.2 to 8.7)
   Greater (150% of primary model)                                         666.3 (288.2 to 1,003.5)                                         66.3 (29.3 to 102.4)                                                                                    14.9 (9.2 to 23.5)   1.5 (0.9 to 2.4)                          651.5 (270.8 to 987.6)     65.0 (27.7 to 100.9)   15.5 (6.5 to 23.5)
  Patients aware of having chronic kidney disease avoid salt substitutes   457.1 (195.0 to 699.5)                                           45.5 (19.7 to 71.4)                                                                                     8.5 (5.1 to 13.1)    0.9 (0.5 to 1.4)                          448.5 (185.1 to 693.5)     44.6 (18.8 to 70.6)    10.6 (4.4 to 16.5)
  Alternative blood pressure effects of salt substitutes:                                                                                                                                                                                                                                                                                                            
   About 75% greater[@ref5]                                                646.0 (347.7 to 928.2)                                           65.0 (36.0 to 95.2)                                                                                     10.6 (6.4 to 16.6)   1.1 (0.6 to 1.7)                          635.0 (335.0 to 920.2)     63.9 (35.0 to 94.2)    15.1 (8.0 to 21.8)
   About 100% greater[@ref6]                                               716.2 (544.9 to 892.6)                                           72.1 (54.0 to 92.4)                                                                                     10.6 (6.4 to 16.6)   1.1 (0.6 to 1.7)                          706.2 (536.5 to 883.3)     71.0 (53.1 to 91.3)    16.8 (12.7 to 21.1)
   About 180% greater[@ref24]‡ **\[**                                      961.4 (777.3 to 1,138.4)                                         97.1 (76.9 to 118.2)                                                                                    10.6 (6.4 to 16.6)   1.1 (0.6 to 1.7)                          950.9 (769.2 to 1,123.9)   95.9 (75.8 to 117.2)   22.6 (18.4 to 26.8)
   Effect only in patients with hypertension                               349.7 (156.2 to 534.0)                                           34.8 (15.5 to 55.0)                                                                                     10.6 (6.4 to 16.6)   1.1 (0.6 to 1.7)                          338.3 (141.3 to 524.8)     33.8 (14.3 to 54.0)    8.1 (3.4 to 12.5)
  Dose-response relation of serum to dietary potassium intake:                                                                                                                                                                                                                                                                                                       
   Stronger§                                                               460.7 (196.3 to 704.4)                                           45.9 (19.8 to 71.9)                                                                                     11.9 (6.9 to 19.1)   1.2 (0.7 to 1.9)                          448.2 (185.3 to 695.9)     44.6 (18.6 to 70.6)    10.7 (4.4 to 16.5)
   Weaker¶                                                                 460.7 (196.3 to 704.4)                                           45.9 (19.8 to 71.9)                                                                                     7.5 (4.7 to 11.7)    0.8 (0.5 to 1.2)                          452.8 (187.3 to 699.3)     45.0 (19.1 to 71.2)    10.8 (4.5 to 16.6)
   Equal over chronic kidney disease stages G3a-G5                         460.7 (196.3 to 704.4)                                           45.9 (19.8 to 71.9)                                                                                     5.8 (3.6 to 9.0)     0.6 (0.4 to 0.9)                          454.9 (190.6 to 699.5)     45.2 (19.2 to 71.3)    10.8 (4.5 to 16.7)

SBP=systolic blood pressure; UI=uncertainty interval; CVD=cardiovascular disease; CKD=chronic kidney disease.\*Include deaths from ischaemic heart disease, stroke (ischaemic and haemorrhagic), and other cardiovascular diseases (aortic aneurysm, hypertensive heart disease, atrial fibrillation, cardiomyopathy, peripheral artery disease, and other cardiovascular and circulatory diseases).

Adults aged ≥25 years were considered exposed.

Hernandez et al conducted meta-analyses to evaluate the effect of salt substitutes on blood pressure and 24 hour potassium excretion.[@ref24] Estimates for excretion of potassium in 24 hours (11.5 mmol/day, 95% confidence interval 8.4 to 14.6) were multiplied by a factor of 1.3 to estimate the corresponding increase in potassium intake and changed the assumptions of the effects of blood pressure and potassium intake in the sensitivity analysis.

Increasing exponentially with decreasing kidney function.

Increasing linearly with decreasing kidney function.

![Ratio of averted-to-additional deaths from cardiovascular disease in individuals with chronic kidney disease and in the total adult population in China, including individuals with chronic kidney disease, estimated by the primary model and by one way deterministic sensitivity analyses. Diamonds represent point estimates and error bars 95% uncertainty intervals. Values above one indicate net benefit (that is, greater number of deaths averted from reduction in systolic blood pressure than additional deaths from increased serum potassium). Hernandez et al conducted meta-analyses to evaluate the effect of salt substitutes on blood pressure and excretion of potassium in 24 hours.[@ref24] The estimates for excretion of potassium (11.5 mmol/day, 95% confidence interval 8.4 to 14.6) were multiplied by a factor of 1.3 to estimate the corresponding increase in potassium intake and changed the assumptions of the effects of blood pressure and potassium intake in the sensitivity analysis](marm052964.f2){#f2}

Sensitivity analyses
--------------------

Although the estimates of absolute averted and additional deaths varied in the sensitivity analyses (eFigs 4-5), substantial net benefits were consistently seen in the total population ([table 4](#tbl4){ref-type="table"}) and in those with chronic kidney disease ([table 3](#tbl3){ref-type="table"}), with averted deaths far outweighing additional deaths ([fig 2](#f2){ref-type="fig"}). A 50% greater or lesser use of salt substitutes would increase or decrease the number of averted (total and net) and additional deaths by around 50%, respectively, compared with the primary model, but the ratio of averted to additional deaths would be largely unchanged. Although having a minimal effect on averted deaths (1% fewer), avoidance of salt substitutes in patients with chronic kidney disease aware of their diagnosis reduced the estimated additional deaths by 20% and resulted in 8% more net averted deaths compared with the primary model. Comparing the effects on systolic blood pressure from the three meta-analyses, rather than the Salt Substitute and Stroke Study, increased the estimated averted deaths compared with the primary model. When we used the effects on systolic blood pressure from Peng et al, 40% more averted deaths were estimated, and from Newberry et al, 55% more averted deaths were estimated ([table 4](#tbl4){ref-type="table"}).[@ref5] [@ref6] When we simultaneously used the effect on systolic blood pressure and potassium dose estimated in a recent meta-analysis by Hernandez et al, the averted deaths increased (109% more) but additional deaths related to hyperkalaemia were reduced (30% fewer).[@ref24] Assuming a blood pressure effect only in individuals with hypertension, the number of averted deaths was reduced to 76% of the primary model.

When we assumed an exponential increase in the dose-response relation between dietary and serum potassium by decreasing kidney function, the additional deaths increased by 12%. When we assumed a linear relation or a constant response in chronic kidney disease stages G3a-G5, additional deaths decreased by 29% and 45%, respectively. Altering the standard deviations of the distributions of systolic blood pressure in each group had a negligible effect on the results (data not shown). When we changed the content of potassium chloride in the salt substitute and the proportion of discretionary salt replaced by salt substitutes (eFig 5), estimates of additional deaths varied from about 600 (10% discretionary salt replaced with salt substitutes containing 10% potassium chloride) to around 13 000 additional deaths (100% discretionary salt replaced with salt substitutes containing 25% potassium chloride). In the total population and in individuals with chronic kidney disease, the assumptions about coverage and the effects of blood pressure affected net averted deaths the most, whereas the assumptions about the dose-response relation between dietary and serum potassium had a limited effect (eFig 4). In the hypothetical worst case scenario, the highest number of estimated additional deaths were seen (about 16 000; 95% uncertainty interval 9325 to 26 119), although there were substantial net averted deaths from cardiovascular disease in the total population (around 492 000; 95% uncertainty interval 208 103 to 751 855) and in those with chronic kidney disease (about 21 000; −1187 to 44 778).

Discussion
==========

Based on comparative risk assessment models, a nationwide intervention to replace normal discretionary salt with potassium enriched salt substitutes in China could prevent around 460 000 deaths from cardiovascular disease, 740 000 non-fatal cardiovascular events, and 8 million disability adjusted life years annually. We estimated that the intervention could prevent about one in nine deaths from cardiovascular disease in China, and that the averted deaths could greatly outweigh additional deaths related to hyperkalaemia. The intervention was also estimated to be net life saving in the subgroup of people with chronic kidney disease, with three averted deaths from a reduction in systolic blood pressure for each death related to hyperkalaemia.

Policy implications
-------------------

Our study has important implications. Increased systolic blood pressure is the leading cause of preventable death worldwide,[@ref3] [@ref25] with an especially high burden in China and similar nations where consumption of dietary sodium is high and consumption of potassium is low.[@ref1] Excess consumption of sodium is estimated to contribute to one in seven deaths from cardiovascular disease in China.[@ref4] In contrast with most Western countries where the predominant source of sodium is in pre-prepared and packaged foods,[@ref26] the major source of sodium in China is discretionary.[@ref1] Hence replacement of normal cooking and table salt with potassium enriched salt substitutes is a practical approach to reduce consumption of sodium in China. Our findings suggest that this intervention would have a large effect on the burden of cardiovascular disease in China. Although the proportion of sodium intake from processed and pre-prepared foods in China is increasing[@ref1] and the effect of salt substitution could decline in the future, even 50% of the estimated intervention effects would constitute a large net benefit, with more than 200 000 averted deaths from cardiovascular disease annually. We also recognise that a few observational studies have suggested J-shaped associations of consumption of sodium with cardiovascular disease.[@ref27] But these relations are caused by measurement errors in the estimation of consumption of sodium.[@ref28] Even if the associations were true, the studies would not be relevant to China where mean intake of sodium is much higher than any putative nadir of risk.[@ref27] Also, studies on salt substitutes[@ref6] (including the Salt Substitute and Stroke Study) showed modest reductions in dietary sodium with concomitant increases in dietary potassium, and even observational studies suggesting J-shaped associations for dietary sodium showed linearly increasing risk for the ratio of dietary sodium to potassium.[@ref27]

Our model used data on reductions in systolic blood pressure from an ongoing population-wide intervention to encourage replacement of discretionary salt with potassium enriched salt substitutes in northern China. Thus our modelling implicitly incorporated important factors, such as achieved intensity, coverage, and compliance of this intervention. Because the Salt Substitute and Stroke Study is a large scale pragmatic trial, its effects are likely to reasonably approximate what a national scale intervention can achieve. Evidence suggests that the palatability of salt substitutes will not be a major barrier in China, which was confirmed in the interim measurements of the Salt Substitute and Stroke Study where 98% of households randomised to the intervention used salt substitutes.[@ref12] Even if all discretionary salt was replaced with potassium enriched salt substitutes, mean intake of sodium in China would still exceed the recommendations of the World Health Organization. Thus promotion of salt substitutes should be (as in the Salt Substitute and Stroke Study)[@ref11] accompanied by educational campaigns to use the salt substitute more sparingly, and not more often, than standard salt. Other national government initiatives to reduce consumption of salt in the general population have succeeded when they were multifaceted and included structural activities.[@ref29] Given the increasing contribution of processed foods to consumption of sodium in China over recent years,[@ref1] an intervention that also encourages the use of salt substitutes in food reformulation, as a means of reducing sodium in processed foods, combined with substitution of discretionary salt, could further enhance the benefits to the whole population.[@ref30]

The evidence suggests that salt substitutes lower systolic blood pressure, which is likely the result of reduced dietary sodium[@ref4] and increased consumption of potassium.[@ref20] The absolute magnitude of the reduction in systolic blood pressure anticipated from a nationwide salt substitute intervention is uncertain and is unlikely to be as large as that reported in the carefully controlled trials included in previous meta-analyses.[@ref5] [@ref6] Hence we used estimates of the effects on systolic blood pressure from a contemporary, large scale, and long term pragmatic trial in China,[@ref11] which will likely be more applicable and will more reliably estimate the effects of a national intervention in China than meta-analyses of a few smaller and less generalisable studies. The effects of salt substitution on systolic blood pressure in the Salt Substitute and Stroke Study were smaller than those reported in previous meta-analyses, suggesting that our primary results are appropriately conservative. Sensitivity analyses, which showed further reductions in the systolic blood pressure lowering effect by 50%, identified substantial numbers of averted cardiovascular events and overall net benefits.

Comparison with other studies
-----------------------------

Inconsistent results from benefit and risk assessments on the potential use of salt substitutes in European countries have been found, likely related to differences in methodology.[@ref31] [@ref32] [@ref33] In two studies, consumption of potassium in the Netherlands[@ref32] and Norway[@ref33] after nationwide salt substitution was predicted and compared with dietary guidelines and putative safety levels. In another study, the incidence of life threatening hyperkalaemia caused by a hypothesised salt substitution in the UK was predicted. None of these assessments, however, estimated the effects on blood pressure and cardiovascular disease. The benefits of strategies to reduce sodium (including salt substitutes) on cardiovascular disease in China have been modelled,[@ref38] but potential risks were not estimated and the evaluation did not provide estimates for important subgroups, such as those with chronic kidney disease. Our findings extend previous studies by quantifying the potential net effects (benefits and harms) from a nationwide salt substitution intervention.

Concerns about the potential harms of potassium enriched salt substitutes in chronic kidney disease are largely based on case reports, which mostly describe non-fatal events in people consuming salt substitutes with a high content (\>40%) of potassium chloride. We identified only one report of a fatal event; a middle aged man died after a suspected suicide by consuming a large amount (21 g) of salt substitute (53% potassium), leading to severe hyperkalaemia and cardiac arrest.[@ref39] Only limited evidence, therefore, links increased consumption of potassium from salt substitutes and the risk of hyperkalaemia. Nevertheless, we modelled potential harms of potassium enriched salt substitutes in individuals with chronic kidney disease to conservatively estimate the net effect of salt substitutes. All findings, including sensitivity analyses that assumed a greater dose-response between dietary and serum potassium, suggested net cardiovascular benefits of potassium based salt substitution in individuals with chronic kidney disease. Given these estimated benefits, strategies to mitigate the risk of hyperkalaemia by encouraging individuals with chronic kidney disease to avoid salt substitutes in a national intervention could result in net harm (because of missed cardiovascular disease benefits) in this subpopulation. Our results suggest that alternative strategies should be evaluated to minimise the risk in the population but retain the benefits, such as increased screening for chronic kidney disease and enhanced monitoring of serum concentrations of potassium in patients, especially in those with advanced disease where the risk is greatest.

Other interventions for chronic diseases also have adverse effects but a favourable net benefit. For example, a common serious side effect of drugs that block the renin-angiotensin-aldosterone system is angioedema, which occurred in 0.68% of patients receiving enalapril.[@ref34] Metformin, a widely used glucose lowering agent, can cause fatal lactic acidosis (1.1-3.9 deaths per 100 000 patient years), especially in patients with advanced chronic kidney disease.[@ref35] In comparison, the risk of salt substitutes, estimated by the primary model and in sensitivity analyses, was 0.6-1.5 deaths per 100 000 people exposed.

Limitations of this study
-------------------------

Our investigation has potential limitations. The estimated effect of the intervention on systolic blood pressure was based on a study that recruited individuals with prevalent stroke or hypertension and might not be generalisable to the whole Chinese population. Net benefits did not change greatly in sensitivity analyses, however, when we excluded any health benefits in people with normal blood pressure or assumed a 50% lower effect on systolic blood pressure. We did not evaluate the cost effectiveness or the national feasibility of our modelled nationwide salt substitution intervention. We did not explicitly evaluate alternative policies (eg, partial price subsidy funded by the government), which could have an effect on the use of salt substitutes.[@ref36] Estimates from our sensitivity analysis assuming 50% of the salt substitute use and systolic blood pressure effect of the Salt Substitute and Stroke Study, however, suggested substantial net benefits overall and in those with chronic kidney disease.

Although providing salt substitutes free of charge is a possible approach to reduce medical costs related to cardiovascular disease, more studies are needed to investigate which combination of intervention strategies might be preferable to policy makers in China. We did not consider the additional benefits of partial salt substitution on non-cardiovascular outcomes, such as stomach cancer, which is prevalent in parts of China, or pre-eclampsia in pregnant women, which might lead to underestimation of the net benefits of the intervention. Future studies should evaluate the benefits of potassium enriched salt substitutes in specific subpopulations, such as pregnant women, and for the prevention of non-cardiovascular disease outcomes.

Evidence to confirm the dose-response relation between dietary and serum potassium in patients with chronic kidney disease is limited, and is not from Asian populations, and we incorporated the uncertainty in these estimates into all analyses. Our sensitivity analyses identified only a modest impact of changing the dose-response assumptions, with central estimates of additional deaths from cardiovascular disease ranging from 5403 (assuming similar responses between dietary and serum potassium in chronic kidney disease stages G3a-G5) to 11 893 (assuming an exponential increase in responses between dietary and serum potassium with reduced kidney function). We did not incorporate any potential benefits of increased consumption of potassium for individuals with hypokalaemia. Estimates of cardiovascular disease burden before the intervention were based on the Global Burden of Disease Study, and although the methodology behind these estimates is continuously improving, estimations of rare diseases and non-fatal outcomes might be less accurate.[@ref13] [@ref14] [@ref15] Although most of our data on China were from 2015, data on the prevalence of chronic kidney disease were for 2009-10 and might have modestly changed since that time.[@ref2] [@ref17] The reduction in systolic blood pressure from salt substitutes, however, could eventually decrease the prevalence of chronic kidney disease by reducing the annual number of new cases of chronic kidney disease by almost 7%.

Comparative risk assessment models provide a simple tool to simultaneously model multiple disease processes and risk factors. The disadvantages compared with more complex model approaches, however, include the lack of an explicit time component, failure to allow for recurring events, and inability to model interactions between individuals, populations, or their environment.[@ref37] Our modelling study does not prove that a national intervention to encourage potassium enriched salt substitutes will prevent cardiovascular disease; rather, it provides important quantitative estimates, corresponding uncertainty, and assessments of the sensitivity of the findings to different inputs to guide the design, implementation, and evaluation of an appropriate intervention in a national population.

Strengths of this study
-----------------------

Our study has several strengths. Data were derived, whenever possible, from nationally representative sources, increasing the validity and generalisability of the results. Because obtaining valid estimates of sodium intake are challenging in large populations, we did not rely on estimated intakes of salt or sodium in our primary model. Instead, we used the effects on systolic blood pressure of the intervention from the Salt Substitute and Stroke Study, an ongoing large scale (\>20 000 participants) potassium enriched salt substitute intervention that shows that these interventions are feasible at a scale in China, with clinically meaningful effects on blood pressure.[@ref12] Cardiovascular benefits of lower systolic blood pressure were derived from pooled analyses of large prospective studies with further accounting for age specific effects. Clinical trial data were used to estimate the dose-response relation between dietary and serum potassium in individuals with chronic kidney disease. Data on risk of cardiovascular death and serum concentrations of potassium in individuals with chronic kidney disease, and data on the risk of cardiovascular disease by serum concentrations of potassium, were from pooled analyses of multiple prospective cohorts. We used comparative risk models to estimate benefits, risks, and the net effects, jointly incorporating the uncertainties of all inputs. We conducted a suite of additional sensitivity analyses to assess the influence of varying model inputs and assumptions, supporting the robustness of the findings.

Conclusions
-----------

A nationwide intervention to encourage the use of potassium enriched salt substitutes was estimated to substantially reduce deaths from cardiovascular disease, non-fatal cardiovascular events, and disability adjusted life years in China, with the benefits outweighing the harms in the overall population and in individuals with chronic kidney disease. Our results suggest that a person in the general population and an individual with chronic kidney disease would be more likely to survive with the intervention than without. Although our estimates can provide guidance to policy makers, large clinical studies (such as the ongoing Salt Substitute and Stroke Study) are needed to evaluate the potential benefits versus harms of salt substitution.

### What is already known on this topic

1.  Replacement of dietary salt with potassium enriched salt substitutes is a promising strategy to reduce blood pressure and prevent cardiovascular disease in China and in other countries where consumption of sodium is high, potassium intake is low, and where the principal source of salt is discretionary

2.  Relative benefits versus harms, in particular the risk of hyperkalaemia and cardiac deaths in individuals with advanced chronic kidney disease, are not established, limiting widespread implementation

### What this study adds

1.  A comparative risk assessment framework, incorporating potential benefits and harms, estimated that replacement of discretionary salt with potassium enriched salt substitutes could prevent nearly 500 000 deaths from cardiovascular disease annually by reducing blood pressure

2.  The increased consumption of potassium could lead to around 10 000 additional deaths related to hyperkalaemia annually in individuals with chronic kidney disease but substantial net benefits would occur in these individuals

3.  Quantitative estimates suggest that nationwide replacement of discretionary salt with potassium enriched salt substitutes could result in large net cardiovascular benefits in China, in the general population and in individuals with chronic kidney disease
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